---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-066426"
form_type: "8-K"
ticker: "MNKD"
cik: "0000899460"
company_name: "MANNKIND CORP"
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T06:23:21.164505+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MannKind Q1 revenue $78M (+18% YoY); net income $13.2M (+24%)

## Summary
- 1Q25 revenue $78.4M (+18% YoY); GAAP net income $13.2M (+24%); non-GAAP net income $21.6M (+43%).
- Royalty revenue $30M (+32%) from increased Tyvaso DPI demand; collaborations & services $29.4M (+18%) from United Therapeutics.
- Afrezza NRx grew 20% YoY; sBLA for pediatric approval expected mid-2025.
- MNKD-101 Phase 3 ICON-1: 55 patients randomized, 85% sites activated; target 100 patients by YE 2025.
- Cash & investments $198M; MNKD-201 (nintedanib DPI) expected to advance to next phase in 2H 2025.

## SEC filing metadata
- accession: 0000950170-25-066426
- form_type: 8-K
- ticker: MNKD
- cik: 0000899460
- company_name: MANNKIND CORP
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899460/000095017025066426/0000950170-25-066426-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899460/000095017025066426/mnkd-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-066426
- JSON: https://secwatch.observer/filing/0000950170-25-066426.json
- Plain text: https://secwatch.observer/filing/0000950170-25-066426.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.